Alzheon Inc.
Researchers are testing an investigational medicine called ALZ-507 in healthy adults between 50 and 75 years of age. The purpose of this study is to learn: Assess if oral ALZ-507 is safe What side effects may occur How the body absorbs ALZ-507 Whether food affects how ALZ-507 is absorbed How much ALZ-507 reaches the blood, cerebrospinal fluid, and urine Participants will receive either ALZ-507 or a placebo. Some participants will receive a single dose, while others will receive daily doses for two weeks. Researchers will monitor participants closely through medical examinations, laboratory testing, and collection of blood, cerebrospinal fluid and urine. The findings from this study will help guide the future development of ALZ-507. The information from this study will help determine whether ALZ-507 is safe for further clinical development.
This is a Phase 1, single-center, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of ALZ-507 following single ascending doses (SAD) and multiple ascending doses (MAD) in healthy adult participants aged 50 to 75 years. ALZ-507 is an investigational oral formulation. The study will evaluate the safety profile of ALZ-507 and characterize its pharmacokinetic properties in plasma, urine, and cerebrospinal fluid (CSF). The study consists of two parts: Part 1: Single Ascending Dose (SAD) Part 1 will evaluate the safety, t…
Inclusion Criteria: * Healthy males and females aged 50 to 75 years, inclusive * Body mass index 18.0 to 35.0 kg/m2, inclusive, and \>50 kg body weight * No clinically significant values for vital signs (systolic blood pressure \[BP\] 90 to 140 mmHg, diastolic BP 40 to 90 mmHg, and HR 50 to 100 bpm) and no clinically significant ECG readings, as determined by the principal investigator or sub investigator Exclusion Criteria: * Participation in a clinical research study within the previous 30 days or within a period of less than 5 times the drug's half-life * Have previously participated in…
Participants will receive ALZ-507 oral capsules administered as single ascending doses in Part 1 or once daily for 14 days as multiple ascending doses in Part 2
Matching placebo capsules administered orally according to the same dosing schedule as ALZ-507
Arctuva estimate
Verify or correct the compensation shown for this listing.